These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 28972975)

  • 21. The cost and cost-effectiveness of gender-responsive interventions for HIV: a systematic review.
    Remme M; Siapka M; Vassall A; Heise L; Jacobi J; Ahumada C; Gay J; Watts C
    J Int AIDS Soc; 2014; 17(1):19228. PubMed ID: 25373519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of and Financial Returns to Voluntary Medical Male Circumcision for HIV Prevention in South Africa: An Incremental Cost-Effectiveness Analysis.
    Haacker M; Fraser-Hurt N; Gorgens M
    PLoS Med; 2016 May; 13(5):e1002012. PubMed ID: 27138961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The president's fiscal year 2007 initiative for human immunodeficiency virus counseling and testing expansion in the United States: a scenario analysis of its coverage, impact, and cost-effectiveness.
    Holtgrave DR
    J Public Health Manag Pract; 2007; 13(3):239-43. PubMed ID: 17435490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis on funds application of community based organizations involved in HIV/AIDS response and government financial investment in China, 2014].
    Zhang G; Zhu YX; Wang P; Liu P; Li JF; Sha S; Yang WZ; Li H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Mar; 51(3):232-236. PubMed ID: 28260337
    [No Abstract]   [Full Text] [Related]  

  • 25. Asia can afford universal access for AIDS prevention and treatment.
    Komatsu R; McLeod R; Sarkar S; Siripong N; Gupta I; Tangcharoensathien V; Brown T; Jeugmans J; Avila-Figueroa C; Atun R
    AIDS; 2010 Sep; 24 Suppl 3():S72-9. PubMed ID: 20926931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Global Fund to fight HIV/AIDS, TB and Malaria 5-y: evaluation policy issues].
    Kerouedan D
    Bull Soc Pathol Exot; 2010 May; 103(2):119-22. PubMed ID: 20376595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
    Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
    Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural interventions to prevent HIV/sexually transmitted disease: are they cost-effective for women in the southern United States?
    Cohen DA; Wu SY; Farley TA
    Sex Transm Dis; 2006 Jul; 33(7 Suppl):S46-9. PubMed ID: 16794555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa.
    Wilkinson D; Floyd K; Gilks CF
    S Afr Med J; 2000 Aug; 90(8):794-8. PubMed ID: 11022629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence.
    Creese A; Floyd K; Alban A; Guinness L
    Lancet; 2002 May; 359(9318):1635-43. PubMed ID: 12020523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of expenditure analysis to enhance returns on investments in HIV services.
    Honermann B; O'Hagan R
    Curr Opin HIV AIDS; 2017 Sep; 12(5):494-500. PubMed ID: 28639989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lives Saved Tool (LiST) costing: a module to examine costs and prioritize interventions.
    Bollinger LA; Sanders R; Winfrey W; Adesina A
    BMC Public Health; 2017 Nov; 17(Suppl 4):782. PubMed ID: 29143622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal investment in a portfolio of HIV prevention programs.
    Zaric GS; Brandeau ML
    Med Decis Making; 2001; 21(5):391-408. PubMed ID: 11575489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allocative and implementation efficiency in HIV prevention and treatment for people who inject drugs.
    Benedikt C; Kelly SL; Wilson D; Wilson DP;
    Int J Drug Policy; 2016 Dec; 38():73-80. PubMed ID: 27883944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation.
    Delva W; Wilson DP; Abu-Raddad L; Gorgens M; Wilson D; Hallett TB; Welte A
    PLoS Med; 2012; 9(7):e1001239. PubMed ID: 22802729
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.